Entasis Therapeutics (NASDAQ:ETTX) Issues Earnings Results, Beats Expectations By $0.60 EPS
Entasis Therapeutics (NASDAQ:ETTX) announced its quarterly earnings data on Thursday. The company reported ($0.27) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.87) by $0.60, Fidelity Earnings reports. The company had revenue of $7.00 million for the quarter.
ETTX stock traded down $0.07 during mid-day trading on Friday, hitting $5.01. 10,500 shares of the company were exchanged, compared to its average volume of 12,547. The company has a market capitalization of $73.42 million, a PE ratio of -0.41 and a beta of 3.01. The company has a current ratio of 9.11, a quick ratio of 9.11 and a debt-to-equity ratio of 0.03. Entasis Therapeutics has a twelve month low of $3.97 and a twelve month high of $9.25. The firm has a fifty day simple moving average of $5.89 and a 200 day simple moving average of $6.43.
Several research analysts have weighed in on ETTX shares. Zacks Investment Research raised shares of Entasis Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, October 15th. HC Wainwright started coverage on shares of Entasis Therapeutics in a report on Monday, August 19th. They set a “buy” rating and a $18.00 price objective for the company. Finally, ValuEngine raised shares of Entasis Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday.
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
Recommended Story: Capital gains and your 401(k) or IRA
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.